ReviewVaccines2024
Recent Scientific Advancements towards a Vaccine against Group A
Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.NPJ vaccines · 2026Review
- Development of a Novel Polyleucine-Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Development of an inhibitory monoclonal nanobody targeting Streptococcus pyogenes siderophore binding protein FtsB.The Journal of biological chemistry · 2026Article
- Molecular epidemiology and antimicrobial susceptibility of group A Streptococcus isolated from children in Greece during 2023.Infection · 2026Article
- Targeting Streptococcus pyogenes atpF protein for multi-epitope vaccine development: a genomics-driven immunoinformatics strategy.Journal, genetic engineering & biotechnology · 2025Article
- Successful Transition to Whole-Genome Sequencing and Bioinformatics to Identify Invasive Streptococcus spp. Drug Resistance, Alaska, USA.Emerging infectious diseases · 2025Article
- Invasive Group A Streptococcal Infection in Children, 1992-2023.JAMA network open · 2025Article
- A rapid approach for linear epitope vaccine profiling reveals unexpected epitope tag immunogenicity.Scientific reports · 2025Article
- Epitope Mapping with Sidewinder: An XL-MS and Structural Modeling Approach.International journal of molecular sciences · 2025Article
- Peritonsillar abscess in children: A retrospective analysis on surgical and antimicrobial approaches.PloS one · 2025Article
- A mini review of the pathogenesis of acute rheumatic fever and rheumatic heart disease.Frontiers in cellular and infection microbiology · 2025Review
- Recent Advances on the Prevention and Management of Rheumatic Heart Disease.Global heart · 2025Review
- Group A Streptococcus Infections in Children: Epidemiological Insights Before and After the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2024Review
- Respiratory tract infections: an update on the complexity of bacterial diversity, therapeutic interventions and breakthroughs.Archives of microbiology · 2024Review
- Mechanisms that potentially contribute to the development of post-streptococcal glomerulonephritis.Pathogens and disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Group A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.